These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. Stevenson W; Gaffey M; Ishitani M; McCullough C; Dickson R; Caldwell S; Lobo P; Pruett T Transplant Proc; 1995 Feb; 27(1):1219-21. PubMed ID: 7878856 [No Abstract] [Full Text] [Related]
7. Resiquimod 3M. Jones T Curr Opin Investig Drugs; 2003 Feb; 4(2):214-8. PubMed ID: 12669385 [TBL] [Abstract][Full Text] [Related]
8. Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection. Gardelli C; Attenni B; Donghi M; Meppen M; Pacini B; Harper S; Di Marco A; Fiore F; Giuliano C; Pucci V; Laufer R; Gennari N; Marcucci I; Leone JF; Olsen DB; MacCoss M; Rowley M; Narjes F J Med Chem; 2009 Sep; 52(17):5394-407. PubMed ID: 19725579 [TBL] [Abstract][Full Text] [Related]
9. Approaches for the development of antiviral compounds: the case of hepatitis C virus. Schinazi RF; Coats SJ; Bassit LC; Lennerstrand J; Nettles JH; Hurwitz SJ Handb Exp Pharmacol; 2009; (189):25-51. PubMed ID: 19048196 [TBL] [Abstract][Full Text] [Related]
10. Progress and development of small molecule HCV antivirals. Ni ZJ; Wagman AS Curr Opin Drug Discov Devel; 2004 Jul; 7(4):446-59. PubMed ID: 15338954 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Thomson JA; Perni RB Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221 [TBL] [Abstract][Full Text] [Related]
12. The new era of hepatitis C treatment: still the tip of the iceberg? Gasbarrini A; Ponziani FR; Annichiarico BE; Siciliano M; Craxì A Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2271-4. PubMed ID: 24065217 [No Abstract] [Full Text] [Related]
13. Development of novel agents for the treatment of hepatitis C virus. Swan T; Chung RT Hepatology; 2008 Apr; 47(4):1426. PubMed ID: 18322936 [No Abstract] [Full Text] [Related]
14. Novel hepatitis C drugs in current trials. Kronenberger B; Welsch C; Forestier N; Zeuzem S Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427 [TBL] [Abstract][Full Text] [Related]
15. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine. Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593 [TBL] [Abstract][Full Text] [Related]
16. HCV compound in trials. AIDS Patient Care STDS; 2000 May; 14(5):285-6. PubMed ID: 10833820 [No Abstract] [Full Text] [Related]
17. New therapeutic options for hepatitis C. Waters L; Nelson M Curr Opin Infect Dis; 2006 Dec; 19(6):615-22. PubMed ID: 17075339 [TBL] [Abstract][Full Text] [Related]
18. Virology: fresh assault on hepatitis C. Rice CM Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912 [No Abstract] [Full Text] [Related]
19. Competition intensifies around hepatitis C. Dorey E Nat Biotechnol; 2009 Apr; 27(4):305-6. PubMed ID: 19352356 [No Abstract] [Full Text] [Related]
20. Tailoring antiviral therapy in hepatitis C. Davis GL Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667 [No Abstract] [Full Text] [Related] [Next] [New Search]